A new furoxan NO-donor rabeprazole derivative and related compounds

被引：19

作者：

Sorba, G

Galli, U

Cena, C

Fruttero, R

Gasco, A

Morini, G

Adami, M

Coruzzi, G

Brenciaglia, MI

Dubini, F

机构：

[1] Univ Turin, Dipartimento Sci & Tecnol Farmaco, I-10125 Turin, Italy

[2] Univ Piemonte Orientale, Dipartimento Sci Chim Alimentari Farmaceut & Farm, I-28100 Novara, Italy

[3] Univ Parma, Dipartimento anat Umana Farmacol & Sci Med Forens, I-43100 Parma, Italy

[4] Univ Roma La Sapienza, Dipartimento Sci & Sanita Pubbl G Sanarelli, I-00186 Rome, Italy

[5] Univ Milan, Ist Microbiol, I-20133 Milan, Italy

来源：

CHEMBIOCHEM | 2003年 / 4卷 / 09期

关键词：

drug design; furoxans; medicinal chemistry; nitric oxide; rabeprazole;

D O I：

10.1002/cbic.200300617

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Stomach pump: Gastric antisecretory and protective activity against damaging agents are shown by the pump inhibitor rabeprazole (1). This compound is also potently active against Helicobacter pylori strains that are resistant to metronidazole. Modification of 1 with a furazan or furoxan group significantly reduced its antisecretory potency but not its efficacy. The furoxan analogue, which can act as an NO donor, has a protective activity comparable to that of the parent molecule.

引用

页码：899 / 903

页数：5

共 25 条

[11] Prevention of acute NSAID-related gastroduodenal damage - A meta-analysis of controlled clinical trials [J].